Multimeric Interferon Alpha for Localized Cancer Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly bone, skin, subcutaneous, mucosal, and submucosal cancers, lack effective and easily administered methods to alleviate pain and treat the diseases effectively.
Innovation Solution
Administration of consensus interferon alpha with anti-cancer activity, specifically through percutaneous, transmucosal, inhalation, and systemic routes, targeting affected areas directly or indirectly to provide relief and treat cancer cells, including the use of formulations like aerosolized interferon and transdermal patches for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then cancer can be treated, but treatment effectiveness is insufficient and administration is complex
Solution Approach 1:
The invention segments the interferon molecule into multiple copies (至少2个，优选3-10个) linked together to form a multimeric structure. This segmentation approach enhances treatment effectiveness by increasing antiviral and tumor-inhibitory activity while maintaining manageable administration through various delivery routes including percutaneous, transmucosal, inhalation, and injection methods
Solution Approach 2:
The consensus interferon alpha multimer exhibits multiple functions: it demonstrates enhanced antiviral activity, tumor-inhibitory effects, and pain relief capabilities. The single composition can treat various cancer types including bone cancer, skin cancer, subcutaneous cancer, mucosal cancer, and submucosal cancer, as well as provide analgesic effects for cancer-related pain, thereby simplifying the treatment regimen
2Adaptability or versatility
If interferon is administered systemically, then cancer treatment coverage is broad, but pharmacokinetics and side effects worsen
Solution Approach 1:
The invention enables localized administration of interferon through percutaneous and transmucosal routes, allowing the drug to be delivered directly to the affected tissue or systemically through absorption. This localized approach maintains broad treatment coverage for various cancer types while reducing systemic exposure and associated side effects. The multimeric structure also provides controlled release, further minimizing harmful effects
Data Source
AI summary
The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.